Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production
Copyright © 2021 by The American Association of Immunologists, Inc..
Phosphatidylserine (PS)-targeting monoclonal Abs (mAbs) that directly target PS and target PS via β2-gp1 (β2GP1) have been in preclinical and clinical development for over 10 y for the treatment of infectious diseases and cancer. Although the intended targets of PS-binding mAbs have traditionally included pathogens as well as stressed tumor cells and its associated vasculature in oncology, the effects of PS-targeting mAbs on activated immune cells, notably T cells, which externalize PS upon Ag stimulation, is not well understood. Using human T cells from healthy donor PBMCs activated with an anti-CD3 + anti-CD28 Ab mixture (anti-CD3/CD28) as a model for TCR-mediated PS externalization and T cell stimulation, we investigated effects of two different PS-targeting mAbs, 11.31 and bavituximab (Bavi), on TCR activation and TCR-mediated cytokine production in an ex vivo paradigm. Although 11.31 and Bavi bind selectivity to anti-CD3/28 activated T cells in a PS-dependent manner, surprisingly, they display distinct functional activities in their effect on IFN-γ and TNF-ɑ production, whereby 11.31, but not Bavi, suppressed cytokine production. This inhibitory effect on anti-CD3/28 activated T cells was observed on both CD4+ and CD8+ cells and independently of monocytes, suggesting the effects of 11.31 were directly mediated by binding to externalized PS on activated T cells. Imaging showed 11.31 and Bavi bind at distinct focal depots on the cell membrane. Collectively, our findings indicate that PS-targeting mAb 11.31 suppresses cytokine production by anti-CD3/28 activated T cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:207 |
|---|---|
| Enthalten in: |
Journal of immunology (Baltimore, Md. : 1950) - 207(2021), 2 vom: 15. Juli, Seite 436-448 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Calianese, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
82115-62-6 |
|---|
| Anmerkungen: |
Date Completed 25.10.2021 Date Revised 25.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4049/jimmunol.2000763 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327623276 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327623276 | ||
| 003 | DE-627 | ||
| 005 | 20231225201208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.2000763 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327623276 | ||
| 035 | |a (NLM)34215655 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calianese, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.10.2021 | ||
| 500 | |a Date Revised 25.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by The American Association of Immunologists, Inc. | ||
| 520 | |a Phosphatidylserine (PS)-targeting monoclonal Abs (mAbs) that directly target PS and target PS via β2-gp1 (β2GP1) have been in preclinical and clinical development for over 10 y for the treatment of infectious diseases and cancer. Although the intended targets of PS-binding mAbs have traditionally included pathogens as well as stressed tumor cells and its associated vasculature in oncology, the effects of PS-targeting mAbs on activated immune cells, notably T cells, which externalize PS upon Ag stimulation, is not well understood. Using human T cells from healthy donor PBMCs activated with an anti-CD3 + anti-CD28 Ab mixture (anti-CD3/CD28) as a model for TCR-mediated PS externalization and T cell stimulation, we investigated effects of two different PS-targeting mAbs, 11.31 and bavituximab (Bavi), on TCR activation and TCR-mediated cytokine production in an ex vivo paradigm. Although 11.31 and Bavi bind selectivity to anti-CD3/28 activated T cells in a PS-dependent manner, surprisingly, they display distinct functional activities in their effect on IFN-γ and TNF-ɑ production, whereby 11.31, but not Bavi, suppressed cytokine production. This inhibitory effect on anti-CD3/28 activated T cells was observed on both CD4+ and CD8+ cells and independently of monocytes, suggesting the effects of 11.31 were directly mediated by binding to externalized PS on activated T cells. Imaging showed 11.31 and Bavi bind at distinct focal depots on the cell membrane. Collectively, our findings indicate that PS-targeting mAb 11.31 suppresses cytokine production by anti-CD3/28 activated T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a CD28 Antigens |2 NLM | |
| 650 | 7 | |a CD3 Complex |2 NLM | |
| 650 | 7 | |a Muromonab-CD3 |2 NLM | |
| 650 | 7 | |a Phosphatidylserines |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a bavituximab |2 NLM | |
| 650 | 7 | |a Q16CT95N25 |2 NLM | |
| 700 | 1 | |a Kreiss, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Kasikara, Canan |e verfasserin |4 aut | |
| 700 | 1 | |a Davra, Viralkumar |e verfasserin |4 aut | |
| 700 | 1 | |a Lahey, Kevin C |e verfasserin |4 aut | |
| 700 | 1 | |a Gadiyar, Varsha |e verfasserin |4 aut | |
| 700 | 1 | |a Geng, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sukhwinder |e verfasserin |4 aut | |
| 700 | 1 | |a Honnen, William |e verfasserin |4 aut | |
| 700 | 1 | |a Jaijyan, Dabbu Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Reichman, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Siekierka, John |e verfasserin |4 aut | |
| 700 | 1 | |a Gennaro, Maria Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Kotenko, Sergei V |e verfasserin |4 aut | |
| 700 | 1 | |a Ucker, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Brekken, Rolf A |e verfasserin |4 aut | |
| 700 | 1 | |a Pinter, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Birge, Raymond B |e verfasserin |4 aut | |
| 700 | 1 | |a Choudhary, Alok |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology (Baltimore, Md. : 1950) |d 1945 |g 207(2021), 2 vom: 15. Juli, Seite 436-448 |w (DE-627)NLM000018554 |x 1550-6606 |7 nnns |
| 773 | 1 | 8 | |g volume:207 |g year:2021 |g number:2 |g day:15 |g month:07 |g pages:436-448 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4049/jimmunol.2000763 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 207 |j 2021 |e 2 |b 15 |c 07 |h 436-448 | ||